Bikbov Boris, Bieber Brian, Andrusev Anton, Tomilina Natalia, Zemchenkov Alexander, Zhao Junhui, Port Friedrich, Robinson Bruce, Pisoni Ronald
Department of Nephrology, A.I.Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russian Federation.
Department of Nephrology Issues of Transplanted Kidney, Academician V.I.Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation.
Hemodial Int. 2017 Jul;21(3):393-408. doi: 10.1111/hdi.12503. Epub 2016 Oct 27.
There is little comparable information about hemodialysis (HD) practices in low- and middle income countries, including Russia. Evaluation of HD in Russia and its international comparisons could highlight factors providing opportunities for improvement.
We examined treatment patterns for 481 prevalent HD patients in 20 Russian facilities, and compared them to contemporary data for 8512 patients from 311 facilities in seven European countries, Japan, and North America. Data were collected according to the uniform methodology of the Dialysis Outcomes and Practice Patterns Study, phase 5.
Compared to other regions, Russian patients were younger (mean age 53.4 years), had a lower percent of males (52.5%), higher arteriovenous fistula use (89.7%), and longer treatment time (mean: 252 minutes, SD: 37 minutes). Mean single pool Kt/V was 1.49 (SD 0.58). Prescription of dialysate calcium 3.5 mEq/L and aluminum-based phosphate binders were high (15.2% and 17.6% of patients, respectively), while intravenous vitamin D and cinacalcet were low (3.3% and 2.2%, respectively). The percents with parathyroid hormone >600 pg/mL (30.9%) and serum phosphate >1.78 mmol/L (37.7%) were high. Use of erythropoetin stimulating agents (78%) was lower, but hemoglobin, ferritin, and transferrin saturation were generally comparable to North America and Europe.
These detailed data for hemodialysis in Russia demonstrate that many practice patterns contrasted sharply to those in Europe, Japan, and North America, while other features were similar. Our analysis revealed several positive and some less favorable treatment patterns in Russia that represent opportunities for improving patient care and outcomes.
包括俄罗斯在内的低收入和中等收入国家,关于血液透析(HD)实践的可比信息很少。对俄罗斯血液透析情况及其国际比较进行评估,可能会突出那些提供改进机会的因素。
我们研究了俄罗斯20家机构中481例维持性血液透析患者的治疗模式,并将其与来自欧洲七个国家、日本和北美的311家机构中8512例患者的当代数据进行比较。数据是根据透析结果和实践模式研究第5阶段的统一方法收集的。
与其他地区相比,俄罗斯患者更年轻(平均年龄53.4岁),男性比例较低(52.5%),动静脉内瘘使用率较高(89.7%),治疗时间较长(平均:252分钟,标准差:37分钟)。平均单池Kt/V为1.49(标准差0.58)。透析液钙3.5 mEq/L和铝基磷酸盐结合剂的处方率较高(分别为患者的15.2%和17.6%),而静脉注射维生素D和西那卡塞的处方率较低(分别为3.3%和2.2%)。甲状旁腺激素>600 pg/mL(30.9%)和血清磷酸盐>1.78 mmol/L(37.7%)的患者比例较高。促红细胞生成素刺激剂的使用率较低(78%),但血红蛋白、铁蛋白和转铁蛋白饱和度总体上与北美和欧洲相当。
这些关于俄罗斯血液透析的详细数据表明,许多实践模式与欧洲、日本和北美形成鲜明对比,而其他特征则相似。我们的分析揭示了俄罗斯一些积极和一些不太有利的治疗模式,这些模式代表了改善患者护理和治疗结果的机会。